SCHEMBL2471272

SCHEMBL2471272

COc1cccc(O)c1C(=O)NC(C1(c2cccc(F)c2)CCNCC1)S(=O)(=O)Nc1ccc(F)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNLIP P16233 1/20 0.34
SMN1; SMN2 Q16637 5/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 2/20 0.33
LMNA P02545 4/20 0.33
HPGD P15428 1/20 0.33
SOAT1 P35610 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
GAA P10253 1/20 0.32
ALOX12 P18054 1/20 0.32
CRHBP P24387 1/20 0.32
CRHR2 Q13324 1/20 0.32
TSHR P16473 1/20 0.32
POLB P06746 1/20 0.32
USP2 O75604 1/20 0.32
CYP2D6 P10635 1/20 0.32
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2469967 0.89 SOAT1 (0.35) PNLIPSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL2468487 0.86 ALDH1A1 (0.33) NPC1ALDH1A1SOAT1POLB
SCHEMBL2469411 0.85 SMN1; SMN2 (0.34) SMN1; SMN2ALDH1A1KDM4ESOAT1KMT2A
SCHEMBL2471510 0.84 SOAT1 (0.34) ALDH1A1SOAT1TSHR
SCHEMBL2470579 0.84 KMT2A (0.34) PNLIPKMT2A
SCHEMBL2492124 0.83 SOAT1 (0.32) ALDH1A1SOAT1TSHR
SCHEMBL2468085 0.83 SOAT1 (0.32) SOAT1TSHR
SCHEMBL2702902 0.81 KDM4E (0.40) SMN1; SMN2ALDH1A1KDM4ELMNAHPGD
SCHEMBL2493197 0.81 SOAT1 (0.33) SMN1; SMN2SOAT1KMT2AUSP2CYP2D6
SCHEMBL2472448 0.81 GAA (0.41) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 PNLIP 3636/4885SMN1; SMN2 4032/4885NPC1 989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.